About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.

The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm

Clinicaltrials.gov identifier NCT03930433

Recruitment Status Completed

First Posted April 29, 2019

Last update posted March 10, 2020

Study Description

Brief summary:

The correlation between endothelial dysfunction and the risk of coronary heart disease is well known through previous studies. The degradation of the function of nitric oxide acting on the endothelium of blood vessels is mainly explained by reduction of synthesis, loss due to oxidative stress, and decreased sensitivity to vascular dilatation action. In particular, patients with high blood pressure have been known to have impaired vascular endothelial function through animal experiments and several clinical studies, mainly due to increased biomechanical friction in the blood vessels and decreased biological availability of nitric oxide, which in turn causes incongruity in the production of nitric monoxide and changes in normal vascular dilatation. There have also been reports recently that early diagnosis and treatment may improve endothelial dysfunction and prevent the progression of coronary artery disease. However, the reality is that the drugs available in vasospastic angina patients with endothelial dysfunction are very limited. Until recently, beta-blockers were reported to inhibit vascular dilatation of adrenaline stimuli, a drug corresponding to relative contraindications in vasospastic angina patients, with one study reporting that propranolol cannot, but rather exacerbates, vasospastic angina. However, a series of reports on the vascular dilatation of the recently developed third-generation beta-blockers have reinvented the role of beta-blockers in vasospastic angina, especially nebivolol (selective, continuous beta-blockers) is known to act on β-1 adrenaline receptor blockings and endothelium to create vascular dilatation, and also to stimulate β-3 adrenaline receptors to cause nitric oxide generation and antioxidant effects in the endothelium of blood vessels. Therefore, this clinical trial seeks to find whether nebivolol will inhibit vascular contraction in hypertensive patients and will work in angiospastic angina patients.

  • Condition or Disease:Coronary Vasospasm
  • Intervention/Treatment: Drug: Nebivolol
    Drug: Diltiazem
    Drug: Nebivolol+Diltiazem
  • Phase: Phase 4
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 51 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Group 1: Nebivolol group Group 2: Diltiazem group Group 2: Nebivolol + Diltiazem group
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment
  • Official Title: The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm
  • Actual Study Start Date: January 2018
  • Actual Primary Completion Date: March 2019
  • Actual Study Completion Date: March 2019
Arms and interventions
Arm Intervention/treatment
Active Comparator: Nebivolol group
Oral Nebivolol 5mg / day (2 weeks) -> 10mg / day (10 weeks)
Drug: Nebivolol
Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Placebo Comparator: Diltiazem group
Oral Diltiazem 90mg / day (2 weeks) -> 180mg / day (10 weeks)
Drug: Diltiazem
Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Placebo Comparator: Nebivolol+Diltiazem group
Oral Nebivolol 2.5mg / day + Oral Diltiazem 45mg / day (2 weeks) -> Oral Nebivolol 5mg / day + Oral Diltiazem 90mg / day (10 weeks)
Drug: Nebivolol+Diltiazem
Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
Outcome Measures
  • Primary Outcome Measures: 1. Changes in coronary spasm [ Time Frame: Baseline to 12 weeks ]
    The descriptive statistics (mean subject number, standard deviation, median value, minimum value, and maximum value) of changes in the baseline and 12-week outcomes will be presented for each treatment group, and the comparison between the three groups for ANOVA or ANOVA Kruskal-Wallis test. Changes in each group will be analyzed using Paired t-test or Wilcoxon signed rank test. An ANCOVA analysis will be performed when there are more influencing factors.
  • Secondary Outcome Measures: 1. Changes in Quality of Life [ Time Frame: Baseline to 12 weeks ]
    Changes in Quality of Life based on Seattle Angina Questionnaire
  • 2. Changes in mean sitting systolic blood pressure and mean sitting diastolic blood pressure [ Time Frame: Baseline to 6, 12 weeks ]
    Changes in mean sitting systolic blood pressure and mean sitting diastolic blood pressure
  • 3. Percentage of target blood pressure reached [ Time Frame: Baseline to 6, 12 weeks ]
    Percentage of target blood pressure reached from baseline to 6, 12 weeks
Eligibility Criteria
  • Ages Eligible for Study: 20 to 80 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- hypertension (stage I-2: Systolic blood pressure 140-179mmHg and diastolic blood
pressure 90-109mmHg)

- 20 to 80 years old

- diagnosed with vasospastic angina through coronary angiography and provocation test

- available to outpatient treatment

- voluntarily signed a written consent to participate in the clinical trial

Exclusion Criteria:

1. Previous history of hypersensitivity to beta blockers or calcium channel blockers

2. History of dementia or accompanying psychiatric illness or history of drug abuse

3. Those who participated in other clinical trials within 1 month before screening

4. A person who is unable to perform compliance with the plan and procedures, or who has
been judged by the tester to be in a medical condition inappropriate for participation

5. Study subjects who are taking drugs that can affect the study drug efficacy evaluation
(ACE inhibitors, angiotensin blockers, beta blockers other than clinical trial drugs,
calcium antagonists other than clinical trial drugs, diuretics other than indapamide).
These subjects are allowed to participate after a wash-out period of at least 2 weeks

6. Malignant hypertension (with retinal hemorrhage or papilledema) or known moderate or
severe retinopathy (retinal hemorrhage within the last 6 months, visual disturbance,
retinal microaneurysm)

7. A history of secondary hypertension and all suspected secondary hypertension:
coarctation of the aorta, hyperaldosteronism, renal artery stenosis, Cushing's
disease, chromatin-positive cell tumor, polycystic kidney disease, etc.

8. Patients with orthostatic hypotension with symptoms

9. Patients with severe heart disease (heart failure New York Heart Association class 3
and 4), recent 6-month ischemic heart disease (angina pectoris, myocardial
infarction), percutaneous coronary intervention, or coronary artery bypass surgery)

10. Patients with severe cerebrovascular disease (stroke, cerebral infarction, cerebral
hemorrhage within the last 6 months)

11. Patients with anuria or severe renal failure (creatinine clearance 3 times the upper limit of normal, biliary
obstruction, biliary cirrhosis, cholestasis

13. Gastrointestinal diseases and surgery patients that may affect the absorption,
distribution, metabolism, and excretion of drugs, current active gastritis and
gastrointestinal / rectal bleeding that the tester considers clinically significant,
active inflammatory bowel syndrome within the last 12 months

14. Pregnant and lactating women, those who have a pregnancy plan during the trial and do
not agree with the appropriate method of contraception

Contacts and Locations
Contacts
Locations

Korea, Republic of
Korea University Anam Hospital
Seoul

Sponsors and Collaborators

Korea University Anam Hospital

Korea University Guro Hospital

Korea Unversity Ansan Hospital

Severance Hospital

More Information
  • Responsible Party: Korea University Anam Hospital
  • ClinicalTrials.gov Identifier: NCT03930433 History of Changes
  • Other Study ID Numbers: NevibololSpasm
  • First Posted: April 29, 2019 Key Record Dates
  • Last Update Posted: March 10, 2020
  • Last Verified: March 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Korea University Anam Hospital: Nebivolol
  • Additional relevant MeSH terms: Coronary Vasospasm